Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00317798 · ClinicalTrials.gov registry record · Phase 1
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00317798 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 18 participants.
The verdict
NCT00317798, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as antithymocyte globulin may stimulate the immune system in different ways and stop cancer cells from growing. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It may also prevent or reduce the side effects of antithymocyte globulin. Giving antithymocyte globulin together with sirolimus may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of antithymocyte globulin when given together with sirolimus in treating patients with relapsed multiple myeloma.
Interventions
- DRUG sirolimus
- BIOLOGICAL anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00317798
The ClinicalTrials.gov registry entry for NCT00317798 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sirolimus is the first listed.
NCT00317798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00317798 about?
NCT00317798 is a clinical study titled "Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma". RATIONALE: Biological therapies, such as antithymocyte globulin may stimulate the immune system in different ways and stop cancer cells from growing. Sirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It may also prevent or reduce the side effects o...
What is the current status of trial NCT00317798?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-04. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00317798?
The interventions under investigation include: sirolimus (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00317798?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.